List of Excipients in Branded Drug NINTEDANIB CAPSULES, 100 MG AND 150 MG

Generic Drugs Containing NINTEDANIB CAPSULES, 100 MG AND 150 MG

Company	Ingredient	NDC	Excipient
EXELAN PHARMACEUTICALS INC	nintedanib	76282-786	FERRIC OXIDE RED
EXELAN PHARMACEUTICALS INC	nintedanib	76282-786	FERRIC OXIDE YELLOW
EXELAN PHARMACEUTICALS INC	nintedanib	76282-786	GELATIN
EXELAN PHARMACEUTICALS INC	nintedanib	76282-786	GLYCERIN

What are the Most Frequently-Used Excipients in NINTEDANIB CAPSULES, 100 MG AND 150 MG?

# Of NDCs	Excipient
1	FERRIC OXIDE RED
1	FERRIC OXIDE YELLOW
1	GELATIN
1	GLYCERIN

Nintedanib Capsules 100 mg and 150 mg: Excipient Strategy, Formulation Barriers, and Commercial Opportunities

Last updated: August 3, 2026

Nintedanib capsules are lipid-filled soft capsules in two strengths: 100 mg and 150 mg of nintedanib, administered as nintedanib esylate. The commercial opportunity is strongest in generic softgel development, regional supply, excipient substitution, and differentiated oral delivery systems. The principal technical challenge is reproducing the reference product’s lipid-based performance, including dissolution, content uniformity, capsule-shell integrity, and fed-state bioequivalence.

The reference product, Ofev, uses a lipid fill containing hard fat, medium-chain triglycerides, and lecithin. Its capsule shell contains gelatin, glycerol, titanium dioxide, and strength-specific colorants. The formulation is designed to support dispersion of a poorly water-soluble active pharmaceutical ingredient and provide consistent absorption after oral administration.[1]

What excipients are used in nintedanib 100 mg and 150 mg capsules?

The US reference formulation uses a relatively compact excipient system.

Formulation component	Reference-product function	Commercial relevance
Nintedanib esylate	Active ingredient	Must be controlled for salt form, particle properties, assay, and impurity profile
Medium-chain triglycerides	Lipid vehicle and solubilization aid	Supports dispersion and absorption; creates sourcing and oxidation-control requirements
Hard fat	Structural lipid and fill-body modifier	Affects viscosity, fill weight, melting behavior, and release
Lecithin	Emulsifier and wetting agent	Helps maintain dispersion of the active in the lipid phase
Gelatin	Softgel shell polymer	Controls mechanical strength, dissolution, moisture transfer, and processing
Glycerol	Plasticizer	Controls shell flexibility and water activity
Titanium dioxide	Opacifier	Relevant to color matching and regional excipient restrictions
Iron oxides or other approved colorants	Strength identification	Supports product differentiation but can complicate global registration

The exact colorant system should be confirmed against the target-market reference label. The 100 mg and 150 mg products use different capsule appearances, which creates an opportunity to use color as a strength-control measure while avoiding unnecessary formulation divergence.[1]

Why is the lipid fill important?

Nintedanib has limited aqueous solubility. A lipid-based fill can improve wetting, dispersion, and apparent solubilization in gastrointestinal fluids. Replacing the reference lipid system with a conventional dry powder capsule can materially alter dissolution and pharmacokinetics.

A generic developer should therefore treat the fill as a performance-critical formulation rather than as an interchangeable excipient package. The critical variables include:

• lipid type and source;
• fatty-acid composition;
• peroxide and anisidine values;
• lecithin grade and phospholipid content;
• fill viscosity at encapsulation temperature;
• nintedanib particle size and wetting;
• water content;
• fill weight and capsule seam integrity; and
• post-encapsulation dissolution.

How should developers design a generic nintedanib softgel?

A reference-matched softgel is the lowest-risk route for a conventional 505(j) or equivalent generic application. The formulation should prioritize bioequivalence and manufacturing reproducibility over excipient novelty.

Recommended development sequence

1. Characterize the reference product’s fill and shell.
2. Screen lipid vehicles with nintedanib esylate under thermodynamic and accelerated-stability conditions.
3. Match the reference product’s viscosity, fill weight, capsule dimensions, and rupture behavior.
4. Compare dissolution in media that reflect both fasted and fed conditions.
5. Conduct pilot bioequivalence studies with a fed arm because food materially affects exposure.
6. Establish strength proportionality between the 100 mg and 150 mg products.
7. Validate commercial-scale encapsulation and shell drying.

The 100 mg and 150 mg strengths should be developed as a coordinated platform. A formulation that is proportional by fill weight is commercially attractive, but the lower strength may present greater content-uniformity risk because of the lower drug-to-excipient ratio.

Can developers use different excipients?

Yes, subject to regulatory acceptability and performance. The main commercial question is whether a substitute excipient delivers equivalent in vitro and in vivo behavior without creating a new clinical or safety issue.

Potential substitutions include:

• alternative medium-chain triglyceride suppliers;
• different grades of hard fat;
• non-animal or plant-derived lecithin;
• gelatin from a different qualified source;
• alternative iron oxide systems;
• modified glycerol levels;
• gelatin-free shell technologies.

Substitution is most defensible when it improves supply security, reduces cost, or addresses regional restrictions. A formulation that changes both the lipid vehicle and shell composition at the same time carries greater comparability risk.

What are the best excipient commercial opportunities for nintedanib capsules?

The most attractive opportunities are concentrated in supply reliability, specialty softgel manufacturing, and differentiated delivery rather than in simple excipient replacement.

1. Regional lipid-excipient supply

Medium-chain triglycerides, hard fats, and lecithin are established pharmaceutical excipients, but supply qualification remains important. Suppliers can differentiate through:

• pharmaceutical-grade documentation;
• tight peroxide specifications;
• low residual solvent levels;
• controlled fatty-acid profiles;
• animal-origin and allergen statements;
• global regulatory packages; and
• dual-site manufacturing.

A qualified secondary source can have high value because lipid excipients affect both product performance and stability.

2. Gelatin and shell-system alternatives

A gelatin softgel is the most direct reference-product approach. Commercial opportunities also exist for:

• fish gelatin;
• bovine or porcine gelatin with documented regional acceptability;
• gelatin-free polysaccharide shells;
• starch- or carrageenan-based shells; and
• vegetarian soft capsules.

A gelatin-free shell could support markets with religious, dietary, or animal-origin restrictions. It would also create a larger regulatory and bioequivalence package because shell composition can affect rupture time, dissolution, moisture migration, and stability.

3. Oxidation-control services

The lipid fill is vulnerable to oxidative degradation. Excipient suppliers and contract manufacturers can offer value through:

• low-peroxide lipid grades;
• nitrogen blanketing;
• oxygen-reduced encapsulation;
• oxygen-scavenging packaging;
• light-protective blister systems; and
• validated stability-indicating methods.

This is a practical opportunity because oxidation control can reduce batch failures without changing the active ingredient.

4. Contract softgel manufacturing

Nintedanib is a suitable product for manufacturers that have:

• small- and medium-batch softgel capacity;
• high-potency handling controls;
• lipid-fill development capability;
• automated visual inspection;
• capsule printing and color matching; and
• experience with ANDA or European generic submissions.

The commercial advantage is strongest for regional generic manufacturers that lack their own softgel lines but can obtain a validated formulation and supply agreement.

5. Patient-oriented delivery systems

Nintedanib is associated with gastrointestinal adverse reactions, particularly diarrhea, nausea, vomiting, and abdominal discomfort.[1] An excipient strategy cannot eliminate these pharmacologic effects, but it can support more consistent administration with food and improve swallowability.

Potential differentiated products include:

• smaller-dimension capsules containing a more concentrated fill;
• modified-color capsules for medication-error reduction;
• unit-dose blister packs;
• calendar packaging;
• adherence-focused packaging for twice-daily dosing; and
• alternative oral dosage forms under a 505(b)(2) or equivalent pathway.

An enteric or delayed-release formulation would require careful development because changing the site and rate of release could alter exposure and safety. It would not be a routine excipient substitution.

What formulation patents protect nintedanib capsules?

Nintedanib is protected by a combination of compound, formulation, manufacturing, and method-of-use rights across jurisdictions. The relevant IP analysis is claim-specific. A generic developer should distinguish between:

• compound patents covering nintedanib or related kinase-inhibitor structures;
• salt-form or crystalline-form patents;
• softgel composition claims;
• lipid-carrier or solubilized formulation claims;
• treatment claims for idiopathic pulmonary fibrosis;
• treatment claims for progressive fibrosing interstitial lung disease;
• treatment claims for systemic sclerosis-associated interstitial lung disease; and
• manufacturing or purification claims.

The reference product’s excipient list does not itself establish freedom to operate. A formulation can use the same excipients while avoiding a patent claim, or use different excipients while still falling within a broader composition claim.

How strong is the formulation patent estate?

The formulation estate is likely more important for a softgel entrant than the excipients themselves. Claims directed broadly to a capsule containing nintedanib in a lipid carrier can create risk even when the developer changes supplier, grade, or concentration.

The strongest formulation claims generally have one or more of the following characteristics:

• narrow excipient ranges;
• defined lipid-to-drug ratios;
• specified dissolution profiles;
• capsule-shell parameters;
• stability limits;
• pharmacokinetic relationships; or
• combinations of nintedanib with food or dosing conditions.

A design-around analysis should test whether the proposed formulation falls within each claim element. Changing only the supplier of medium-chain triglycerides will rarely provide a meaningful design-around if the patent claim is functional or concentration-based.

When does nintedanib lose exclusivity?

Nintedanib’s regulatory exclusivity and patent exclusivity must be analyzed separately.

Exclusivity category	Relevance to nintedanib
New chemical entity exclusivity	Delays certain abbreviated applications after initial approval
Orphan-drug exclusivity	Applied to qualifying indications and approval dates, not automatically to every use
Patent protection	May cover the active ingredient, formulations, uses, or manufacturing
Pediatric exclusivity	Can add six months when granted
Regulatory data exclusivity	Depends on jurisdiction and product classification
Market exclusivity for later indications	May be narrower than exclusivity for the original approval

The FDA first approved Ofev for idiopathic pulmonary fibrosis in 2014. FDA later expanded the product’s indications, including chronic fibrosing interstitial lung diseases with a progressive phenotype and systemic sclerosis-associated interstitial lung disease.[1,2]

The relevant generic-entry date is therefore not simply the anniversary of the 2014 approval. It depends on listed patents, applicable exclusivity, indication carve-outs, and the legal status of any Paragraph IV challenges.

What is the Orange Book status of Ofev?

Ofev is an FDA-approved prescription product listed in the Orange Book under nintedanib, with 100 mg and 150 mg capsule strengths. The Orange Book identifies patents and regulatory exclusivities that may affect abbreviated applications.[3]

A current entry strategy should evaluate:

• every patent listed against the 100 mg and 150 mg capsules;
• patent expiration and pediatric-extension dates;
• whether a patent covers the product, formulation, or method of use;
• whether a proposed label can omit protected indications;
• whether a Paragraph IV certification is available;
• whether a section viii statement can omit a method-of-use patent; and
• whether the reference sponsor has initiated litigation.

Orange Book status can change through patent-listing updates, delisting, pediatric extensions, court decisions, and settlement agreements. It should be reviewed immediately before filing and again before launch.

Which companies are challenging nintedanib exclusivity?

Publicly identifiable challenges should be assessed through FDA Paragraph IV notices, district-court dockets, ANDA litigation records, and regulatory databases. A company’s development of a nintedanib generic does not establish that it has filed an ANDA or made a Paragraph IV certification.

The principal competitive groups are likely to include:

• established generic manufacturers with softgel capacity;
• specialty manufacturers focused on respiratory and fibrosis products;
• regional companies with local registration pathways;
• contract development and manufacturing organizations; and
• companies pursuing alternative oral formulations.

Because nintedanib requires a softgel or equivalent lipid-based platform, the competitive field is narrower than for a conventional immediate-release tablet. Manufacturing capability is a meaningful barrier to entry.

What Paragraph IV and litigation risks exist?

A Paragraph IV challenge could target:

• compound patents;
• formulation patents;
• method-of-use patents;
• crystalline or salt-form patents; or
• manufacturing patents.

The commercial outcome depends on the strength of the asserted claims, the timing of litigation, and whether the generic label can omit patented indications. A skinny-label strategy may be commercially viable if the largest unprotected indication remains available, but it can be constrained by prescribing patterns and substitution rules.

Key litigation questions include:

1. Has the reference sponsor listed a formulation patent against both strengths?
2. Are method-of-use claims separately listed?
3. Does the proposed label include all approved indications?
4. Are the asserted claims vulnerable to anticipation or obviousness challenges?
5. Does the formulation reproduce a claimed lipid system?
6. Is there a settlement restricting launch timing or permitting an authorized generic?

No settlement should be assumed from the absence of a public launch. Generic development may also be delayed by formulation, manufacturing, or regulatory issues.

How does nintedanib compare with competing antifibrotic drugs?

Nintedanib competes primarily with pirfenidone in idiopathic pulmonary fibrosis. The formulation and excipient strategies differ materially.

Product	Dosage form	Core formulation issue	Generic opportunity
Nintedanib/Ofev	Lipid-filled soft capsule	Solubilization, softgel manufacture, fed-state exposure	Technically constrained but potentially less crowded
Pirfenidone/Esbriet	Immediate-release tablets or capsules	High-dose oral delivery and tolerability	More conventional solid-dose manufacturing
Newer antifibrotic candidates	Varies	Molecule-specific solubility and exposure	Depends on clinical and patent outcomes

Nintedanib’s twice-daily regimen contrasts with pirfenidone’s higher daily pill burden. A generic nintedanib product that matches capsule performance, reduces supply interruptions, and offers competitive packaging can gain share without introducing a new dosage form.

What geographic opportunities exist for nintedanib excipients and generics?

The largest commercial opportunity is in jurisdictions where patent and regulatory barriers have cleared but local softgel capacity remains limited.

United States

The 505(j) route is the principal pathway for a therapeutically equivalent generic. Fed bioequivalence, capsule performance, manufacturing controls, and Orange Book patent certifications are central issues.[3,4]

European Union

A decentralized or centralized generic strategy may be appropriate depending on the product and target markets. Excipients must comply with European Pharmacopoeia requirements and local labeling rules. Gelatin origin, titanium dioxide policy, and colorant restrictions require market-by-market review.

Japan

Softgel manufacturing, excipient documentation, and local bioequivalence expectations can create distinct development requirements. Japanese packaging and labeling may also support a separate commercial presentation.

Emerging markets

The opportunity often lies in local supply, lower manufacturing cost, and access to chronic-disease therapies. However, local patent enforcement, reference-product requirements, and pharmacopoeial standards vary significantly.

What manufacturing and IP barriers affect nintedanib capsules?

The main barriers are:

• high-potency active handling;
• control of lipid oxidation;
• softgel encapsulation know-how;
• fill-weight uniformity;
• shell drying and moisture control;
• dissolution reproducibility;
• fed-state bioequivalence;
• source qualification for animal-derived excipients;
• colorant and titanium dioxide restrictions;
• patent claims covering lipid formulations; and
• supply continuity for pharmaceutical-grade lipids.

A developer with an existing softgel platform can reduce cost and time by using a common shell process, but the nintedanib fill still requires product-specific optimization. A developer starting without softgel infrastructure faces a higher capital burden and greater technical risk.

What is the highest-value excipient strategy?

The preferred strategy is a reference-matched lipid softgel using qualified, dual-sourced excipients and a robust oxidation-control program.

A practical target product profile is:

• 100 mg and 150 mg soft capsules;
• hard fat, medium-chain triglycerides, and lecithin or justified alternatives;
• gelatin shell unless a differentiated regional opportunity supports a non-gelatin design;
• strength-specific color coding;
• opaque, light-protective packaging;
• demonstrated fed and fasted dissolution performance;
• dual sourcing for every critical lipid excipient;
• validated stability through the proposed shelf life; and
• an IP design-around supported by claim-chart analysis.

The strongest commercial case is a reliable, lower-cost generic with equivalent performance, rather than a heavily differentiated excipient system that increases regulatory and bioequivalence risk.

Key Takeaways

• Nintedanib 100 mg and 150 mg are lipid-filled soft capsules, not straightforward powder-filled generics.
• The reference fill uses hard fat, medium-chain triglycerides, and lecithin.
• Lipid selection affects solubilization, dissolution, stability, and bioequivalence.
• The best near-term opportunity is a reference-matched generic softgel with secure excipient sourcing.
• Gelatin-free shells and alternative oral dosage forms offer differentiation but carry higher regulatory risk.
• Oxidation control, shell integrity, and fed-state pharmacokinetics are critical development factors.
• Orange Book patents and method-of-use claims must be reviewed before selecting a Paragraph IV or section viii strategy.
• Manufacturing capability is a material barrier and may limit competition relative to conventional solid oral products.
• Commercial success will depend on reliable supply, competitive pricing, regional registration, and accurate indication labeling.

FAQs

Can nintedanib capsules be formulated without lecithin?

Yes, but removing lecithin can change wetting, dispersion, viscosity, dissolution, and absorption. The substitute system must be justified through comparative formulation and bioequivalence work.

Are nintedanib soft capsules suitable for vegetarian markets?

The reference product uses a gelatin shell. A vegetarian shell is technically possible, but it requires separate optimization of mechanical strength, moisture transfer, rupture time, dissolution, and stability.

Does changing the lipid supplier avoid a formulation patent?

Usually not. Patent claims may cover excipient classes, concentration ranges, functional properties, or the complete composition. Supplier substitution alone is rarely a reliable design-around.

Is a nintedanib tablet commercially attractive?

A tablet could reduce softgel manufacturing complexity, but it may create substantial bioavailability and bioequivalence risk because the reference product uses a lipid-based fill. A tablet is more likely to require a differentiated regulatory strategy than a conventional generic pathway.

What packaging is best for nintedanib capsules?

Opaque, moisture-protective blister packaging is generally preferred for a lipid-filled softgel. The final package should be selected using stability data addressing oxygen, humidity, light, and capsule-shell interactions.

References

1. U.S. Food and Drug Administration. (2024). Ofev (nintedanib) capsules: Prescribing information. Boehringer Ingelheim Pharmaceuticals, Inc. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/205832s027lbl.pdf

2. U.S. Food and Drug Administration. (2020). FDA approves Ofev for chronic fibrosing interstitial lung diseases with a progressive phenotype. https://www.fda.gov

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

4. U.S. Food and Drug Administration. (2009). Guidance for industry: Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA. https://www.fda.gov

5. International Council for Harmonisation. (2009). Q8(R2) pharmaceutical development. https://www.ich.org

6. United States Pharmacopeia. (2024). USP-NF: General chapters and excipient monographs. United States Pharmacopeial Convention.